XML 65 R56.htm IDEA: XBRL DOCUMENT
v3.25.2

In-Licensing and Supply - Additional Information (Detail) € in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Dec. 31, 2024 USD ($) | Dec. 31, 2024 EUR (€) | Jun. 30, 2018 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Oct. 31, 2024 USD ($) | Sep. 30, 2024 USD ($) | Aug. 31, 2024 USD ($)
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Capitalized milestone payments | $ 7,500,000 |  |  | $ 13,360,000 |  |  | $ 13,360,000 |  |  |  |
Intangible assets, net | 7,371,000 |  |  | 12,972,000 |  |  | $ 12,972,000 |  |  |  |
Ompi Supply Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 3,200,000 | € 3.0 |  |  |  |  |  |  |  |  |
Supply Agreement Expiration Date |  |  |  |  |  |  | Dec. 31, 2035 |  |  |  |
Agreement Termination, Due To Material Breach |  |  |  |  |  |  | 90 days |  |  |  |
Aegis Therapeutics Agreement |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront License Fees |  |  | $ 50,000,000 |  |  |  |  |  |  |  |
Aggregate milestone payments upon achievement of certain sales milestones |  |  |  |  |  |  | $ 20,000,000 |  |  |  |
Regulatory milestone |  |  |  |  |  | $ 1,000,000 | 500,000 |  |  |  |
Milestone payment due |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Capitalized milestone payments |  |  |  |  |  |  |  |  |  | $ 5,000,000 | $ 2,500,000
Notice Period Description |  |  |  |  |  |  | The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement. |  |  |  |
Legal Patent Fees |  |  |  | 0 | $ 0 |  | $ 0 | $ 0 |  |  |
Supply Agreement Expense |  |  |  | $ 0 | $ 0 |  | $ 0 | $ 0 |  |  |
Aegis Therapeutics Agreement | First Commercial Sale Of Neffy |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Capitalized milestone payments |  |  |  |  |  |  |  |  | $ 5,000,000 | 5,000,000 |
Aegis Therapeutics Agreement | Intellectual Property |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Estimated Life of Finite Lived Intangible Assets |  |  |  | 14 years 6 months |  |  | 14 years 6 months |  |  |  |
Aegis Therapeutics Agreement | Intangible Assets |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Capitalized milestone payments |  |  |  |  |  |  |  |  |  | 7,500,000 |
Aegis Therapeutics Agreement | New Drug Application [Member] |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Capitalized milestone payments |  |  |  |  |  |  |  |  |  | $ 2,500,000 |
Renaissance Agreement |  |  |  |  |  |  |  |  |  |  |
In Licensing and Supply [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contract Termination Claims, Description |  |  |  |  |  |  | Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws. |  |  |  |

X
- Definition Aggregate milestone payments upon achievement of certain sales milestones. + References No definition available. + Details
Name: | spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Agreement termination, due to material breach. + References No definition available. + Details
Name: | spry_AgreementTerminationDueToMaterialBreach
Namespace Prefix: | spry_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Capitalized milestone payments. + References No definition available. + Details
Name: | spry_CapitalizedMilestonePayments
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represents in licensing and supply. + References No definition available. + Details
Name: | spry_InLicensingAndSupplyLineItems
Namespace Prefix: | spry_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Legal Patent Fees + References No definition available. + Details
Name: | spry_LegalPatentFees
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment due on achievement of annual sales. + References No definition available. + Details
Name: | spry_MilestonePaymentDueOnAchievementOfAnnualSales
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Notice Period Description + References No definition available. + Details
Name: | spry_NoticePeriodDescription
Namespace Prefix: | spry_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestone. + References No definition available. + Details
Name: | spry_RegulatoryMilestone
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Supply Agreement Expense + References No definition available. + Details
Name: | spry_SupplyAgreementExpense
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Supply agreement expiration date + References No definition available. + Details
Name: | spry_SupplyAgreementExpirationDate
Namespace Prefix: | spry_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront License Fees + References No definition available. + Details
Name: | spry_UpfrontLicenseFees
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront Payment. + References No definition available. + Details
Name: | spry_UpfrontPayment
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 275 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479072/912-275-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 275 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479072/912-275-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 405 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477623/912-405-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 405 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477623/912-405-50-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478685/912-310-50-2 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 912 -SubTopic 275 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479072/912-275-50-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478685/912-310-50-1 + Details
Name: | us-gaap_ContractTerminationClaimsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spry_OmpiSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfNeffyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=spry_IntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spry_NewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RenaissanceLakewoodLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |